Recommendations for management of diabetes during Ramadan: update 2015

Mahmoud Ibrahim,1 Megahed Abu Al Magd,2 Firas A Annabi,3 Samir Assaad-Khalil,4 Ebtesam M Ba-Essa,5 Ibtihal Fahdil,6 Sehnaz Karadeniz,7 Terry Meriden,8 Aly A Mishali,9 Paolo Pozzilli,9 Samad Shera,10 Abraham Thomas,11 Suhad Bahijri,12 Jaakko Tuomilehto,13 Temel Yilmaz,14 Guillermo E Umpierrez,15 on behalf of the International Group for Diabetes and Ramadan (IGDR)


Received 5 April 2015
Revised 2 June 2015
Accepted 3 June 2015

INTRODUCTION

Since the ADA working group report on recommendations for management of diabetes during Ramadan published in 2005 and updated in 2010, many healthcare professionals have submitted inquiries asking for periodic updates every 3–5 years to address the important management issues not covered in previous documents.1 2 Areas of interests include updates on lifestyle intervention and use of new pharmacological agents for the treatment of diabetes. We reviewed the literature and reports on new published data on diabetes education, medical nutrition therapy, and recently introduced antidiabetic medications.

There are several potential benefits of fasting during Ramadan. Fasting helps Muslims to feel compassion for those who are less fortunate and underprivileged; it also allows one to build a sense of self-control and willpower, and learn to control natural urges such as hunger and thirst. These benefits allow Muslims to better resist temptations for daily things that are not necessary, such as unhealthy or harmful substances and behaviors. Fasting also offers a time to ‘purify’ the body and the soul, by developing a greater sense of humility, spirituality, and community involvement. As for the potential physiological benefits, it is believed that intermittent fasting limits energy intake promoting weight loss in obese individuals, which could be cardioprotective.3 It is not known, however, what dietary changes have relevance, or positive or
negative impacts on the management of diabetes during Ramadan. Significant nutritional changes obviously have a major impact on pharmacological and non-pharmacological management of diabetes.

**DIABETES EDUCATION DURING RAMADAN**

Structured diabetes education is an essential tool for the management of diabetes during the fasting period and after breaking the fast during Ramadan. In a retrospective analysis by Bravis et al., patients who received diabetes education had less weight gain and fewer episodes of hypoglycemia compared with a group that did not receive education prior to Ramadan. Diabetes education, including the use of point-of-care (POC) glucose testing, resulted in fewer episodes of hypoglycemia between the start of Ramadan and the end of fasting. Diabetes education also helps to overcome certain barriers to diabetes care such as the misconception that puncturing one’s skin for blood glucose testing during the fast would break the fast.6

**USE OF GLUCOSE-LOWERING MEDICATIONS DURING RAMADAN**

The preferred antidiabetic drugs during Ramadan are agents that provide sustained glucose control during prolonged fasting with low risk of hypoglycemia, especially during the fasting period. Table 1 lists the benefits and concerns of commonly used oral antidiabetic agents during Ramadan. Sulfonylureas and insulin secretagogues are widely used during Ramadan. Recent studies, however, have highlighted an increased risk of hypoglycemia during fasting in patients treated with insulin secretagogues.7–9 The risk of hypoglycemia increases exponentially in elderly patients and patients with renal failure and medical illnesses treated with sulfonylureas. In general, it is recommended that insulin secretagogues should be avoided during periods of prolonged fasting due to the increased risk of hypoglycemia. However, the STEADFAST study, a double-blind randomized controlled trial (RCT), compared vildagliptin with glimepiride as an add-on therapy to metformin during Ramadan. In that study, there were no significant differences in weight, glycated hemoglobin (HbA1c), or in the frequency of hypoglycemia between treatment groups.10 Metformin is the preferred agent for the management of patients with type 2 diabetes. Metformin is associated with a reduction in HbA1c of 1–2% and carries a low risk of hypoglycemia.11 These properties make metformin an attractive therapy for the majority of patients who will undergo prolonged fasting. It should be noted, however, that there are very few prospective RCT specifically designed to determine the safety and efficacy of metformin as monotherapy during Ramadan.12 The VECTOR study compared glipizide and vildagliptin in combination with metformin during Ramadan and reported low rates of hypoglycemia along with a lowering of the HbA1c concentration compared with the glipizide group.13 In these trials, no safety issues were found related to metformin use.

α-Glucosidase inhibitors are used successfully in the Middle Eastern population during Ramadan. The most common adverse events with these agents are gastrointestinal symptoms, usually at the beginning of treatment.14 The risk of hypoglycemia is low when used as monotherapy; there are, however, no prospective studies looking at the safety and efficacy of these agents during prolonged fasting periods.

Thiazolidinediones (TZDs), such as pioglitazone, are effective in lowering glucose by improving glucose uptake in peripheral tissues and by reducing insulin resistance. The use of TZDs is not associated with increased risk of hypoglycemia when used as monotherapy. These agents are effective in improving glucose control, resulting in a reduction of HbA1c between 1% and 2%.15 TZDs have long been thought of as a useful agent during Ramadan because of its low risk of hypoglycemia; however, these agents should be started long before the start of the fast as the maximal antihyperglycemic effect may take up to 10–12 weeks. In addition, long-term treatment with TZDs has been associated with fluid retention, peripheral edema, and weight gain. There is also concern with the higher risk of bone loss and increased risk of fractures seen in postmenopausal women. The safety and efficacy of TZD agents has not been established in clinical trials during Ramadan.

Dipeptidyl peptidase-4 (DPP4) inhibitors have been increasingly used during the past decade for the treatment of patients with type 2 diabetes during Ramadan. These agents work by increasing insulin secretion in a glucose-dependent mechanism; therefore, they are not associated with increased risk of hypoglycemia when used as monotherapy. DPP4 inhibitors also reduce glucagon concentration and delay gastric emptying. These agents are attractive during Ramadan because of the low rate of hypoglycemia. Vildagliptin has been compared with different sulfonylurea agents, with and without metformin combination, during Ramadan. The results of these studies indicate that DPP4 inhibitors are effective in improving glycemic control with low rates of hypoglycemia and less weight gain compared with insulin secretagogues.10 15 16 The vildagliptin expeRience comPaRed wiTh sulfonylUrea obsErved during Ramadan (VIRTUE trial) that compared vildagliptin with sulfonylurea therapy during Ramadan reported a reduction in hypoglycemic events with the use of vildagliptin compared with sulfonylurea agents.16 Similar beneficial effects have also been reported with sitaagliptin therapy during Ramadan.8

Few studies have determined the safety and efficacy of glucagon-like peptide 1 receptor agonists (GLP-1 RA) in patients with diabetes during Ramadan. A recent study of liraglutide compared with insulin secretagogues reported a significant improvement in glycemic control with weight loss with liraglutide treatment compared with patients treated with sulfonylureas.14 Severe
hypoglycemic events were not increased with either treatment, but self-reported hypoglycemia was lower with liraglutide.14

The sodium glucose transporter-2 (SGLT-2) inhibitors are the newest class of approved oral antidiabetic agents for the treatment of type 2 diabetes. By increasing glucosuria, SGLT-2 inhibitors are associated with significant improvements of fasting hyperglycemia and HbA1c concentration, and with low risk of hypoglycemia in patients with type 2 diabetes. These agents, however, are associated with increased risk of urinary tract and genital infections, and with a mild increase in the risk of

Table 1 Pharmacological oral agents for the treatment of type 2 diabetes during Ramadan

<table>
<thead>
<tr>
<th>Generic name</th>
<th>Daily dosage (mg)</th>
<th>Advantages</th>
<th>Concerns</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Insulin secretagogues</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulfonylureas</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glipizide</td>
<td>2.5–20</td>
<td>Lowers HbA1c by 1–2%, high initial response rate, no lag time before</td>
<td>Hypoglycemia, weight gain, need caution in patients with renal and hepatic dysfunction</td>
</tr>
<tr>
<td>Glyburide</td>
<td>1.25–20</td>
<td>Lowers HbA1c by 1–2%, high initial response rate, no lag time before</td>
<td>Hypoglycemia, weight gain, need caution in patients with renal and hepatic dysfunction</td>
</tr>
<tr>
<td>Glimepiride</td>
<td>1–4</td>
<td>Lowers HbA1c by 1–2%, high initial response rate, no lag time before</td>
<td>Hypoglycemia, weight gain, need caution in patients with renal and hepatic dysfunction</td>
</tr>
<tr>
<td>Gliclazide</td>
<td>40–320</td>
<td>Lowers HbA1c by 1–2%, high initial response rate, no lag time before</td>
<td>Hypoglycemia, weight gain, need caution in patients with renal and hepatic dysfunction</td>
</tr>
<tr>
<td>Gliclazide MR</td>
<td>30–60</td>
<td>Lowers HbA1c by 1–2%, high initial response rate, no lag time before</td>
<td>Hypoglycemia, weight gain, need caution in patients with renal and hepatic dysfunction</td>
</tr>
<tr>
<td>Meglitinides</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Repaglinide</td>
<td>0.5–8</td>
<td>Lowers HbA1c by 1–1.5%, shorter half-life than sulfonylureas</td>
<td>Hypoglycemia, weight gain, repeated (before meals) dosing, more expensive than sulfonylureas</td>
</tr>
<tr>
<td>Nateglinide</td>
<td>60–120</td>
<td>Lowers HbA1c by 1–1.5%, shorter half-life than sulfonylureas</td>
<td>Hypoglycemia, weight gain, repeated (before meals) dosing, more expensive than sulfonylureas</td>
</tr>
<tr>
<td><strong>α-Glucosidase inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acarbose</td>
<td>25–150</td>
<td>Lowers HbA1c by 0.5–0.8% lowers postprandial glucose levels without causing hypoglycemia, weight neutral</td>
<td>Less effective in lowering glycemia than metformin or sulfonylureas, increased gas production and GI symptoms</td>
</tr>
<tr>
<td>Miglitol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Insulin sensitizers</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biguanides</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metformin</td>
<td>500–2000</td>
<td>Lowers HbA1c by 1–2%, high initial response rate, long record of relative safety, low risk of hypoglycemia, improved lipid profile, may reduce macrovascular events, low cost</td>
<td>Initial GI side effects common, risk of lactic acidosis, cannot be used in patients with renal dysfunction or hepatic dysfunction</td>
</tr>
<tr>
<td>Thiazolidinediones</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pioglitazone</td>
<td>15–45</td>
<td>Lowers HbA1c by 0.8–1.5%, low risk of hypoglycemia, improved lipid profile</td>
<td>Weight gain, fluid retention causing peripheral edema and/or heart failure, expensive, risk of osteopenia in postmenopausal females</td>
</tr>
<tr>
<td><strong>Incretin agents</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dipeptidyl peptidase-4 inhibitors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sitagliptin</td>
<td>25–100</td>
<td>Lowers HbA1c by 0.6–1%, well tolerated, lowers postprandial glucose levels, weight neutral</td>
<td>More expensive and less potent than metformin and sulfonylureas, some agents require dose adjustment in patients with reduced renal function</td>
</tr>
<tr>
<td>Linagliptin</td>
<td>5</td>
<td>Lowers HbA1c by 0.6–1%, well tolerated, lowers postprandial glucose levels, weight neutral</td>
<td>More expensive and less potent than metformin and sulfonylureas, some agents require dose adjustment in patients with reduced renal function</td>
</tr>
<tr>
<td>Saxagliptin</td>
<td>2.5–5</td>
<td>Lowers HbA1c by 0.6–1%, well tolerated, lowers postprandial glucose levels, weight neutral</td>
<td>More expensive and less potent than metformin and sulfonylureas, some agents require dose adjustment in patients with reduced renal function</td>
</tr>
<tr>
<td>Alogliptin</td>
<td>12.5–25</td>
<td>Lowers HbA1c by 0.6–1%, well tolerated, lowers postprandial glucose levels, weight neutral</td>
<td>More expensive and less potent than metformin and sulfonylureas, some agents require dose adjustment in patients with reduced renal function</td>
</tr>
<tr>
<td>Anagliptin*</td>
<td>200–400</td>
<td>Lowers HbA1c by 0.6–1%, well tolerated, lowers postprandial glucose levels, weight neutral</td>
<td>More expensive and less potent than metformin and sulfonylureas, some agents require dose adjustment in patients with reduced renal function</td>
</tr>
<tr>
<td>Teneligliptin*</td>
<td>20–40</td>
<td>Lowers HbA1c by 0.6–1%, well tolerated, lowers postprandial glucose levels, weight neutral</td>
<td>More expensive and less potent than metformin and sulfonylureas, some agents require dose adjustment in patients with reduced renal function</td>
</tr>
<tr>
<td><strong>Glucagon-like peptide 1 agonists</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exenatide</td>
<td>5–10 mcg two times a day</td>
<td>Lowers HbA1c by 0.8–2%, lowers postprandial glucose levels, low risk of hypoglycemia, may reduce blood pressure, improved lipid profile</td>
<td>High rate of GI side effects, injectable, more expensive than sulfonylureas and metformin</td>
</tr>
<tr>
<td>Liraglutide</td>
<td>0.6–1.8 mg daily</td>
<td>Lowers HbA1c by 0.8–2%, lowers postprandial glucose levels, low risk of hypoglycemia, may reduce blood pressure, improved lipid profile</td>
<td>High rate of GI side effects, injectable, more expensive than sulfonylureas and metformin</td>
</tr>
<tr>
<td>Exenatide ER</td>
<td>2 mg weekly</td>
<td>Lowers HbA1c by 0.8–2%, lowers postprandial glucose levels, low risk of hypoglycemia, may reduce blood pressure, improved lipid profile</td>
<td>High rate of GI side effects, injectable, more expensive than sulfonylureas and metformin</td>
</tr>
<tr>
<td>Dulaglutide</td>
<td>0.75–1.5 mg weekly</td>
<td>Lowers HbA1c by 0.8–2%, lowers postprandial glucose levels, low risk of hypoglycemia, may reduce blood pressure, improved lipid profile</td>
<td>High rate of GI side effects, injectable, more expensive than sulfonylureas and metformin</td>
</tr>
<tr>
<td>Albiglutide</td>
<td>30 mg weekly</td>
<td>Lowers HbA1c by 0.8–2%, lowers postprandial glucose levels, low risk of hypoglycemia, may reduce blood pressure, improved lipid profile</td>
<td>High rate of GI side effects, injectable, more expensive than sulfonylureas and metformin</td>
</tr>
<tr>
<td>Lixisenatide*</td>
<td>10 mcg daily</td>
<td>Lowers HbA1c by 0.8–2%, lowers postprandial glucose levels, low risk of hypoglycemia, may reduce blood pressure, improved lipid profile</td>
<td>High rate of GI side effects, injectable, more expensive than sulfonylureas and metformin</td>
</tr>
<tr>
<td><strong>SGLT-2 inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dapagliflozin</td>
<td>5–10 mg daily</td>
<td>Lowers HbA1c by 0.8–1.5%, low risk of hypoglycemia, weight loss, lower blood pressure</td>
<td>Increases risk of urinary tract infection and genital infections, expensive, risk of dehydration</td>
</tr>
<tr>
<td>Canagliflozin</td>
<td>100–300 daily</td>
<td>Lowers HbA1c by 0.8–1.5%, low risk of hypoglycemia, weight loss, lower blood pressure</td>
<td>Increases risk of urinary tract infection and genital infections, expensive, risk of dehydration</td>
</tr>
</tbody>
</table>

*Not Food and Drug Administration approved.
ER, extended release; GI, glycemic index; HbA1c, glycated hemoglobin; MR, modified release; SGLT-2, sodium glucose transporter-2.
Type 2 diabetes is associated with a progressive decline in insulin secretion and β-cell loss with increased duration of diabetes. Many patients soon after a clinical diagnosis of diabetes need to be treated with insulin injections. Although effective in improving glucose control, insulin treatment is associated with increased risk of hypoglycemia, especially during prolonged fasting. The total insulin dose frequently needs to be adjusted during Ramadan in patients with type 1 or type 2 diabetes. The use of basal (glargine or detemir) and rapid-acting insulin analogs (lispro, aspart, and glulisine) has been shown to be superior to human insulin formulations (NPH and regular) during Ramadan by reducing the risk of hypoglycemia. In one study, the administration of lispro insulin before meals was associated with better glycemic control and with a lower rate of hypoglycemia compared with treatment with regular insulin.18 In another study, switching from premixed insulin formulation (30% regular/70% NPH) to 50 regular/50NPH insulin during the evening meal demonstrated a reduction in HbA1c with less hypoglycemic episodes.19

The use of insulin pump therapy has been shown to be effective in improving glycemic control and in reducing the risk of hypoglycemia in patients with type 1 diabetes during Ramadan. The use of an insulin pump helps to provide a continuous basal rate of insulin during the fasting period and to rapidly cover for meals intake after the breaking of the fast. In one study, patients on insulin pumps were monitored during Ramadan with a continuous glucose-monitoring (CGM) device.20 There was no significant increase in the risk of hypoglycemia when comparing the periods before, during, and after the end of fasting. However, the insulin infusion rate needs to be adjusted, with a reduction in the basal insulin rate during the day and greater postprandial boluses after the breaking of the fast.20 The use of CGM devices have evolved during the past decade from being a research tool to serving as a device useful for clinical care in patients with type 1 and type 2 diabetes. CGM devices provide information about the current glucose concentration, direction, and rate of change in glucose concentration. Since it provides glucose values every 5–10 min 24 h a day, CGM may have an advantage over POC testing with respect to reducing the incidence of severe hypoglycemia during fasting. A recent report reported that the use of CGM reported benefits in detecting hypoglycemia during fasting in insulin-treated patients.21 No randomized controlled studies, however, have studied the impact of CGM in patients with diabetes during Ramadan.

Premixed insulin is a commonly prescribed formulation for the outpatient management of patients with type 2 diabetes. In many Muslim countries, premixed insulins are among the most frequently prescribed formulations in patients with type 2 diabetes. Of concern is the fact that some studies have reported a higher risk of hypoglycemia with the use of premixed insulin formulations compared with basal insulin analogs.22 The safety and efficacy of premixed insulin formulations during Ramadan is not known. Table 2 lists recommendations for insulin self-titration during the Ramadan period. The ‘Low-Ratio Premix Insulin Working Group’ recently reported a practical outline on how to adjust insulin during the fasting period, based on premeal blood glucose levels and the history of hypoglycemia.23 This group also recommended a trial fast for three consecutive days before Ramadan to help in detecting hypoglycemia risk and for guiding the self-titration of premix insulin dosage.

Illustrative examples for risks and recommendations for adjusting glucose-lowering therapy during Ramadan in patients with type 2 diabetes are shown in the management algorithm flow chart (figure 1).

### MEDICAL NUTRITION THERAPY DURING RAMADAN

A number of dietary interventions have been shown to be effective in the management of patients with type 2 diabetes. Of particular interest for Ramadan, the use of the macrobiotic Ma-Pi 2 diet may be considered.24 This diet, conceived by Mario Pianesi, is high in dietary fibers, which is in keeping with the ADA and European nutrition recommendations.25 It is rich in complex carbohydrates, whole grains, vegetables and legumes, and

<table>
<thead>
<tr>
<th>Fasting pre-Iftar</th>
<th>No change</th>
<th>Increase insulin daily dose by 10%</th>
<th>Reduce insulin daily dose by 10%</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;5.5 mmol/L (100–180 mg/dL) or symptoms</td>
<td>Increase insulin daily dose by 20%</td>
<td>Reduce insulin daily dose by 20%</td>
<td></td>
</tr>
<tr>
<td>&lt;3.9 mmol/L (70 mg/dL)</td>
<td>Increase insulin daily dose by 20%</td>
<td>Reduce insulin daily dose by 30–40%</td>
<td></td>
</tr>
<tr>
<td>&lt;2.8 mmol/L (50 mg/dL)</td>
<td>Increase insulin daily dose by 20%</td>
<td>Reduce insulin daily dose by 20%</td>
<td></td>
</tr>
</tbody>
</table>

### Table 2 Algorithm for premixed insulin titration during Ramadan (adapted from Hassanein et al)23

fermented products, and low in unrefined sea salt and green tea, without fat or protein from animal sources (including milk and dairy products) and no added sugars. The first RCT comparing the Ma-Pi 2 diet and a standard diet recommended for patients with type 2 diabetes—the MAcrobiotic DIABetes trial MADIAB—was reported in 2014. Following 21 days on the prescribed diets, administered under supervised conditions, the average daily energy intake was 1803 kcal (12% protein, 15% fat, and 73% complex carbohydrates, with 29 g/1000 kcal fiber) in the Ma-Pi 2 group and 1798 kcal (18% protein, 32% fat, and 49% complex carbohydrates, 

---

**Figure 1** Management algorithm for people with type 2 diabetes intending to fast during Ramadan (HbA1c, glycated hemoglobin; SGLT-2, sodium glucose transporter-2 inhibitors; TZD, thiazolidinedione).
with 20.5 g/1000 kcal fiber) in the control group. Multivariate analysis, adjusted for age, gender, body mass index, and physical activity, showed a significant improvement in fasting blood glucose, postprandial blood glucose, HbA1c, total cholesterol, low-density lipoprotein (LDL) cholesterol, LDL–HDL (high-density lipoprotein) ratio, body weight, waist and hip circumference, and insulin resistance in the Ma-Pi 2 diet treated compared with the control diet. Furthermore, participants in the Ma-Pi 2 group achieved better fasting and postprandial glucose target levels of 6.1 mmol/L and 7.8 mmol/L (<110 mg/dL and <140 mg/dL), respectively, at the end of the 21-day dietary treatment, as well as a reduction of markers of insulin resistance and inflammation.24–26 These features are valuable in the management of type 2 diabetes during Ramadan due to a lower component of complex carbohydrate at the night meal and higher complex carbohydrate at predawn, which is eaten before the beginning of daily fasting.

DATES CONSUMPTION
Daily consumption of dates is a deeply rooted tradition among Muslims, especially during the Ramadan. Most Muslims consume dates when they break their fast (Iftar), either alone or with other food items such as yoghurt. Some people also consume dates at the predawn meal (Suhoor). Dehydrated dates (Tamer) analysis revealed that they are rich in carbohydrates (total sugars: 44–88%), salts, minerals, vitamins, unsaturated fatty acids (0.2–0.5%), proteins (2–6%), and fibers (6–12%).

Consumption of 100 g of dates provides 50–100% of the recommended dietary fiber intake.27 In addition, dates have high fructose content with a 1:1 ratio of fructose and glucose. Since fructose is a more powerful sweetener than glucose, it is less rapidly absorbed than sugar, which results in a relatively low glycemic index (GI).27 28 The GI of most common dates range between 35 and 55, with an average of 42.29 30 There is growing evidence of the beneficial effects of dates in improving glycemic and lipid control in patients with diabetes and a possible reduction in cardiovascular risk factors.29 More research; however, is needed to study the possible beneficial effects of dates on patients with diabetes during Ramadan.

TARAWEEH PRAYERS
These are long night prayers, which are not obligatory but highly recommended, that last for 1–2 h. Taraweeh prayers can be a strenuous physical activity that could result in dehydration and increased risk of hypoglycemia. Taraweeh prayers should be considered as a part of the daily exercise program. So patients are advised to monitor BG concentration, to eat starchy foods with Iftar, which are digested slowly, and to drink plenty of water before prayers. In addition, patients with diabetes should be advised to consume extra fluids and carbohydrates to treat hypoglycemic events during Taraweeh prayers. Patients with diabetes at risk or with a history of severe or recurrent hypoglycemia should be treated with agents with a low risk of hypoglycemia or advised to reduce the total daily dose of insulin during Ramadan and Taraweeh prayers.31

MISCONCEPTIONS ABOUT DRAWING BLOOD AND INSULIN INJECTIONS DURING THE FAST
Contrary to the widespread belief among some Muslim communities that injection invalidates the fast, patients should be instructed that insulin injections have no nutrition value and that they are allowed, regardless of whether they are given by the subcutaneous, intramuscular, or intravenous route.32

There is a popular belief that pricking the finger for POC testing breaks the fast, which may lead to patients skipping glucose testing during Ramadan. Again, patients and family members should be educated that similar to injections, puncturing the skin with glucose monitoring devices are allowed, and that glucose monitoring may help in assessing glucose control and in recognizing hypoglycemia during Ramadan. A retrospective study assessed the beliefs and practices of people with diabetes about skin pricking for blood glucose testing during Ramadan fasting. Despite 57% of the study population being literate, 77% of patients did not perform blood glucose monitoring. A large number of patients with diabetes who did not perform monitoring believed that skin pricking during fasting would make the fast void; as a consequence, 40% of participants who were taking insulin never checked their blood glucose levels during fasting.6 The low rates of glucose monitoring may result in a higher risk of hypoglycemia in insulin-treated patients with diabetes.33

To prevent hypoglycemia in diabetes during fasting, healthcare providers need to emphasize the importance of regular glucose monitoring for maintenance of normoglycemia and that skin pricking during fasting does not invalidate the fasting state.34 All people with diabetes who choose to fast should be trained to monitor their blood glucose, to recognize symptoms and signs of hypoglycemia, and to learn about the management and risks associated with severe hypoglycemic events. In addition, patients should be counseled about breaking the fast in the presence of hypoglycemia.35

LIFESTYLE CHANGES AFTER RAMADAN
The end of Ramadan is followed by a 3-day festival known as Eid ul-Fitr. This is usually marked with festivities, sharing of food, and sweet beverages. Patients with diabetes should be advised about the risks of hyperglycemia during this time, as many individuals overindulge in eating and drinking. When the month of Ramadan ends, the patients’ therapeutic regimen should be adjusted and may be changed back to its previous
schedule, if glycaemic control was satisfactory before Ramadan.31

ADDITIONAL REGIONAL PECULIARITIES

Egypt

According to the latest version of the International Diabetes Federation Atlas, the number of adult people with diabetes in Egypt is approximately 7.6 million.36 The vast majority of Muslims with diabetes will practice fasting during the month of Ramadan, even in the presence of diabetic complications. People from some Gulf and North African countries break the fast in the evenings with water and light snacks, followed by consumption of the main meal ~2 h after breaking the fast. In contrast, people in Egypt consume the main meal immediately after breaking the fast. Of interest, physicians should be aware that many people in Egypt during Ramadan consume an extra meal after midnight, replacing the predawn meal, while others may skip the predawn meal. These differences in nutritional intake may have an impact on the management of patients with diabetes and require medication adjustments to maintain glucose control and diminish the risk of hypoglycemia. Unfortunately, no previous studies have reported on the best treatment regimens in different Muslim populations during Ramadan.

Turkey

In Turkey, despite Islam being the most prevalent religion, no previous studies have investigated the effects of fasting on glucose control or the availability of diabetes education. Some small short-term studies have reported no significant effects of fasting on metabolic parameters including glucose control and weight change between the start of fasting and the end of Ramadan in patients with type 2 diabetes.37 Of interest, despite the fact that the majority of patients in these studies were treated with a variety of oral antidiabetic agents, the rate of hypoglycemia is low with few patients experiencing glucose levels of less than 2.2 mmol/L (40 mg/dL) or symptoms of neuroglycopenia.37 38

Ramadan in Pakistan

Approximately 96.4% of the population of Pakistan is Muslim. Few studies have reported on glucose control or the impact of Ramadan on diabetes control in this population. Approximately 73% of patients with diabetes in Pakistan undergo fasting during the month of Ramadan, with a mean age of 50.3±13 years. Among them, 4% have type 1 diabetes and 96% have type 2 diabetes. In Pakistan, patients with diabetes fast for an average of 20–25 days during the month of Ramadan. While the prevalence of hypoglycemia and hyperglycemia has been reported in 4% and 8%, respectively, only 23% of patients with diabetes practice glucose monitoring during the fasting period.39 One study reported that 18% of patients experience one or more episodes of hypoglycemia during the Ramadan period; however, most patients with hypoglycemia did not break their fast.33 Of interest, there does not appear to be a significant difference in the total number of calories consumed during the Ramadan period, and it is not clear if there is a significant difference in glucose control during the fasting period.39 In addition, few patients require hospitalization for glycaemic irregularities during fasting, and there are no increased rates of diabetic ketoacidosis during fasting.

RECOMMENDATIONS FOR THE PREVENTION AND TREATMENT OF HYPOGLYCEMIA DURING RAMADAN

Box 1 lists the recommendations for prevention of hypoglycemia during the Ramadan season. In general, and Ramadan periods.21 39 It showed worse glycemic control in insulin-treated and sulfonylurea-treated patients compared with those on DPP4 inhibitors, metformin, or diet alone. These differences in glycemic control were exaggerated during Ramadan fasting and were more pronounced after Iftar.21 39

Box 1 Recommendations for prevention of hypoglycemia during Ramadan

► Blood glucose monitoring. Depending on treatment regimen, monitor glucose levels daily or several times a day. Patients treated with insulin and insulin secretagogues should measure glucose before, during, and after fasting (2–4 times daily)
► Consultation with diabetes healthcare provider for medication adjustment. Treatment regimen should be evaluated and modified according to glycemic control and risk of hypoglycemia, at least 1 month prior to Ramadan. Avoid or reduce sulfonylureas and/or insulin daily dosage
► Avoid skipping predawn meals
► Avoid strenuous physical activity during fasting period
► Adjust medication dose and eat a snack in the presence of hypoglycemia (see box 2). Consider breaking the fast if there is severe or recurrent hypoglycemia
► Record blood glucose measures to determine patterns contributing to hypoglycemia
CONCLUSION

Much of what is recommended for the management of patients with diabetes during fasting in Ramadan is based on expert opinion, and few randomized controlled studies have investigated best treatment regimens during Ramadan in patients with diabetes. Yet, since the last consensus publication, several antidiabetic medications have become available for the treatment of patients with diabetes.

Patients should be stratified into their risk of hypoglycemia and/or the presence of complications prior to the beginning of fasting. Patients at high risk of hypoglycemia and with multiple diabetic complications should be advised against prolonged fasting. Agents such as metformin, α-glucosidase inhibitors, TZDs, and DPP4 inhibitors appear to be safe and do not need major dose adjustments. Sulfonylureas and insulin secretagogues should be used with extreme caution during Ramadan fasting, in particular chlorpropamide or glyburide, which are associated with increased risk of hypoglycemia. The dose of sulfonylureas should be reduced or the medication stopped before the start of the fast, depending on the degree of glycemic control, kidney function, and presence of diabetic complications. There is increasing knowledge on the efficacy and safety of DPP4 inhibitors as monotherapy or in combination with metformin therapy. The use of DPP4-inhibitors appears to be safe and with low rates of hypoglycemia. The use of GLP-1 RA may also be of benefit in obese patients in improving glycemic control and in reducing appetite during Ramadan. There is no data on the safety and efficacy of SGLT-2 inhibitors during the fasting period of Ramadan.

Patients with type 1 and type 2 diabetes treated with insulin should be educated on the appropriate use of insulin administration and the need for glucose monitoring during the fasting period. Most patients require a modification of the basal insulin dosage and on the use of premeal insulin to cover meals after breaking of the fast. In some patients, a larger insulin dose may be needed after a large evening meal. The use of basal insulin analogs and continuous insulin infusion may be of benefit as they cover basal requirements without significant peaks and may result in less hypoglycemia compared with human NPH and premixed insulin. The drawbacks of insulin analogs and insulin pump therapy are the cost and limitations of technology support in some countries. Finally, patients should be instructed that POC testing does not break the fast and that glucose monitoring may reduce the risks of hypoglycemia in patients receiving insulin secretagogues and insulin therapy.

Author affiliations
1EDC, Center for Diabetes Education, McDonough, Georgia, USA
2Department of Internal Medicine, Mansura University, Mansura, Egypt
3Islamic Hospital, Amman, Jordan
4Department of Internal Medicine, Unit of Diabetes & Metabolism, Alexandria Faculty of Medicine, Alexandria, Egypt
5Dammam Medical Complex, Dammam, Saudi Arabia
6Eastern Mediterranean Office of the World Health Organization, Cairo, Egypt
7Florence Nightingale Istanbul Hospital, Istanbul, Turkey
8Division of Endocrinology, University of IL, Chicago, Illinois, USA
9Department of Endocrinology and Metabolism, University Campus Bio Medico, Rome, Italy
10Diabetic Association of Pakistan, Karachi, Pakistan
11NYU Lutheran, Brooklyn, New York, USA
12Saudi Diabetes Group, King Abdul Aziz University, Jeddah, Saudi Arabia
13National Institute for Health and Welfare, Helsinki, Finland
14Division of Endocrinology and Metabolism, Department of Internal Medicine, Istanbul University, Istanbul, Turkey
15Emory University School of Medicine, Atlanta, Georgia, USA

Contributors MI, JT, and GEU wrote the initial draft of the manuscript. MAAM, FAA, SA-K, EMB-E, IF, SK, TM, AAM, PP, SS, AT, and SB reviewed and edited the manuscript.

Funding GEU is supported in part by research grants from the American Diabetes Association (1-14-LLY-36), and PHS grant UL1 RR025008 from the Clinical and Translational Science Award program, National Institutes of Health, National Center for Research Resources.

Competing interests GEU has received unrestricted research support for inpatient studies (to Emory University) from Sanofi, Merck, Novo Nordisk,
REFERENCES